Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases

Neuro-oncology Advances
Iris M GoldsteinNir Peled

Abstract

Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with increased penetration across the blood-brain barrier compared with previous EGFR-TKIs, and thus, a 52% reduction in the risk of intracranial disease progression is seen when it is used as a first line of therapy compared with gefitinib and erlotinib. It is also efficient as second-line therapy for patients who developed the T790M resistance mutation following treatment with previous generation TKIs. Here, we report 11 patients who were treated by an increasing dose of osimertinib from 80 mg to 160 mg QD orally following intracranial progression in either first- or second-line setting. This is a subcohort analysis from a larger nonrandomized, phase 2, open-label trial, evaluating the efficacy of osimertinib dose escalation from 80 mg to 160 mg in EGFR-mutated advanced non-small-cell lung cancer (NSCLC) patients with intracranial progression in either first- (arm A) or second-line setting (arm B for T790M+ and C for T790M-). Eleven patients, 5 in arm A, 4 in arm B, and 2 in arm C were reported in this study. The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2...Continue Reading

References

Mar 17, 2000·Journal of Neuro-oncology·P D SchellingerA Thron
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takayuki KosakaTetsuya Mitsudomi
Nov 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marissa N BalakWilliam Pao
Jan 7, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nir PeledFred R Hirsch
Oct 28, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christine CordovaMatija Snuderl
Aug 29, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thanyanan ReungwetwattanaJohan Vansteenkiste
Oct 24, 2019·Asia-Pacific Journal of Clinical Oncology·Maverick Wai-Kong Tsang
Nov 22, 2019·The New England Journal of Medicine·Suresh S RamalingamUNKNOWN FLAURA Investigators
Dec 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C H YangMyung-Ju Ahn
Dec 31, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Myung-Ju AhnTony Mok

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Clinical Trials Mentioned

NCT02736513

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.